PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026Clinical and Experimental Dental Research3 citationsOpen Access

USAG‐1 and Regenerative Dentistry, Therapeutic Implications and Future Directions: Review of the Literature

ZMZahra MoradiMKMohammadreza KarimiSKShirin Kolahdouz

Key Points

  • This review evaluates USAG‐1's role in dental tissue repair and its potential as a therapeutic target for tooth regeneration.
  • Analyzed recent studies on USAG‐1's involvement in BMP and Wnt signaling pathways.
  • Examined preclinical models and clinical trial data on USAG‐1 inhibition efficacy.
  • Utilized single-cell RNA sequencing and STRING databases for gene expression analysis.
  • USAG‐1 is expressed in select secretory cell types important for growth and morphogenesis.
  • Inhibition of USAG‐1 promotes tooth regeneration by activating BMP-mediated morphogenesis.
  • Engineered monoclonal antibodies targeting USAG‐1 can facilitate third dentition and reduce congenital tooth agenesis.
  • Ongoing clinical trials suggest promising commercial applications for USAG‐1 therapies.

Abstract

ABSTRACT Objectives Uterine Sensitization‐Associated Gene 1 (USAG‐1) is a bone morphogenetic protein (BMP) antagonist vital for tooth regeneration that is expressed in kidney, gingiva, and dental tissues. Material and methods We analyzed recent studies focusing on USAG‐1 and its involvement in BMP and Wnt signaling pathways related to dental tissue repair and regeneration. Preclinical models and clinical trial data were examined to evaluate the efficacy of USAG‐1 inhibition as a therapeutic strategy. In addition, publicly available single‐cell RNA sequencing and STRING databases were analyzed to investigate the gene expression of USAG‐1 in human tissues and its protein interactions, respectively. Results RNA‐seq analysis confirmed that USAG‐1 is expressed in a subset of secretory cell types in kidney, jaw, and gingiva that are important for cell growth and morphogenesis. Recent studies have also demonstrated that inhibiting USAG‐1 facilitates tooth regeneration by activating BMP‐mediated morphogenesis and improving outcomes in preclinical models. Engineered monoclonal antibodies that target USAG‐1 have shown that blocking the protein product of this gene can promote third dentition and alleviate congenital tooth agenesis. Clinical trials utilizing this antibody are currently underway, with prospects for commercial applications within the next decade. Despite these advancements, challenges related to safety, specificity, and delivery mechanisms remain. Conclusions This review underscores the transformative potential of USAG‐1‐based therapies in regenerative dentistry, offering a paradigm shift in dental care by enabling biologically authentic tooth regeneration. However, the realization of these advancements in clinical practice requires overcoming significant barriers, including ensuring safety, optimizing delivery systems, and addressing ethical concerns. Continued interdisciplinary research is essential to fully harness the potential of USAG‐1 in regenerative dentistry.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Moradi et al. (2026) studied this question.

synapsesocial.com/papers/6984360af1d9ada3c1fb59achttps://doi.org/10.1002/cre2.70301
Ask AI
Helpful
Bookmark
Share
View Full Paper